Does FDA approval of a medical device block my Georgia injury lawsuit?
FDA involvement with a medical device can limit a Georgia injury claim, but it does not automatically end one. The effect depends on how the device went through the agency’s process and on the legal doctrine of federal preemption, which determines whether federal regulation displaces a state-law claim. Because the answer varies by device and theory, FDA approval is a starting point for analysis rather than a blanket bar.
Why the regulatory pathway matters ¶
Medical devices reach the market through different federal routes, and the level of scrutiny varies. Most lower-risk devices clear the FDA through the 510(k) notification process, which asks only whether a device is substantially equivalent to one already sold; higher-risk Class III devices instead go through premarket approval (PMA), a far more rigorous, device-specific review. That difference matters because the express preemption provision of the Medical Device Amendments, 21 U.S.C. § 360k(a), reaches state-law claims only where the FDA has imposed device-specific federal requirements. Courts have held that PMA review creates such requirements, so claims against PMA devices face strong preemption, while 510(k) clearance generally does not, leaving ordinary state-law claims against those devices available. Identifying which pathway a device went through is usually the first step in assessing whether a Georgia claim survives.
What preemption can and cannot reach ¶
Section 360k(a) preemption, where it applies, generally targets state-law claims that would impose requirements different from or in addition to the federal ones. Even for a PMA device, preemption does not wipe out every theory. A so-called parallel claim, one premised on conduct that also violates the federal requirements rather than adding to them, may still proceed. Separately, a “fraud on the FDA” theory is impliedly preempted because policing such fraud is left to the agency. The practical questions often include:
- Whether the device cleared the FDA through 510(k) notification or full premarket approval.
- Whether the specific claim would impose a requirement beyond the federal one.
- Whether the theory parallels a federal requirement rather than conflicting with it.
Because these distinctions are technical, whether a particular claim is barred is a fact-specific legal determination.
The state-law claim underneath ¶
Setting preemption aside, the underlying claim still rests on Georgia product-liability law. O.C.G.A. § 51-1-11 lets an injured patient pursue strict liability against the company that made a defective product, and a device claim of this kind may sound in design, manufacturing, or warnings, with the implanting physician’s role often relevant under the learned-intermediary doctrine. Preemption operates as a filter on which of those claims can go forward, not as a substitute for proving a defect.
The bottom line ¶
FDA approval of a medical device does not automatically block a Georgia lawsuit, but it can limit one through the doctrine of federal preemption, the reach of which depends on the device’s regulatory pathway and the specific claim asserted. Some theories may be barred while others survive, so whether a claim can proceed requires examining both the federal regulatory history and the Georgia product-liability theory involved.
This article is for general educational and informational purposes only and is not legal advice. It does not create an attorney-client relationship, and Georgia law may change. For advice about a specific situation, consult a licensed Georgia personal injury attorney.